A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Hajek, Roman; Pour, Ludek; ÖZCAN, MUHİT; Sanchez, Jesus; Sanz, Ramon; Anagnostopoulos, Achilles; Oriol, Albert; Cascavilla, Nicola; Terjung, Andreas; Lee, Yihua; Briso, Eva; Dobkowska, Edyta; Hauns, Bernhard; Spicka, Ivan

doi:10.1111/ejh.13377

A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Hajek R., Pour L., ÖZCAN M., Sanchez J. M., Sanz R. G., Anagnostopoulos A., ...Daha Fazla

EUROPEAN JOURNAL OF HAEMATOLOGY, cilt.104, sa.5, ss.435-442, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 104 Sayı: 5
Basım Tarihi: 2020
Doi Numarası: 10.1111/ejh.13377
Dergi Adı: EUROPEAN JOURNAL OF HAEMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.435-442
Anahtar Kelimeler: bortezomib, dexamethasone, ibrutinib, multiple myeloma, BRUTON TYROSINE KINASE, TRIAL, MULTICENTER, THERAPY
Ankara Üniversitesi Adresli: Evet

Özet

Objective We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies.